Invivoscribe CEO and leadership

Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® - coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.

Meghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading the Invivoscribe global finance organization, along with human resources and information technology.

Dr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous articles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week.

Dr. Meindert Niemeijer joined Invivoscribe in 2021 as Chief Information Officer. In this role, he is responsible for leading the global bioinformatics, software, and information technology teams. He has a background in Medical Image Analysis and Machine Learning and has more than a decade of experience in the medical device industry creating software-based medical devices.

Dr. Niemeijer came to IVS from Digital Diagnostics where he led the teams that designed, built, documented, and put into production the first autonomous diagnostic Artificial Intelligence (AI), cleared by the FDA. He is an experienced technology leader and deep learning expert passionate about developing AI-based medical devices. During his career, he has built deep expertise in medical device (software) development processes and the way in which these interact with quality management and other regulatory requirements. He loves building and developing technology, processes, and teams.

Dr. Niemeijer obtained a PhD. in Medical Image Analysis and Machine Learning from Utrecht University in the Netherlands. In addition to that, he has an M.Sc. in Medical Computer Science, also from Utrecht University.

Tony Lialin joined Invivoscribe in 2021 as Chief Commercial Officer. In this role, he is responsible for leading the global commercial organization. Mr. Lialin has more than two decades of experience in growing companies in the life sciences industry having held positions in clinical diagnostic, bioinformatics software, instrumentation, and reagent companies.

He has successfully scaled commercial operations at three start-ups resulting in those companies being purchased by large public companies.

Mr. Lialin comes to IVS from Loop Genomics, an NGS long-read sequencing company where he started their global commercial operations growing their business to several million dollars in revenue per year in just three years. From 2014 through June 2018, Mr. Lialin managed $400M in portfolio business at Illumina working closely with customers in the DTC, Oncology, and Postnatal testing spaces. He also served as a director at Agilent Technologies, where he managed the emerging market, field application scientist, technical support, and field service engineering teams. As a six-sigma green belt, he values process, service as a differentiator, and both internal and external customers.

Mr. Lialin earned a BA in Molecular Cellular and Developmental Biology from the University of California at Santa Cruz.

Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® - coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.

Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® - coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.

Dr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous articles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week.